title: Catalytically inactive lipoprotein lipase overexpression increases insulin sensitivity in mice.
abstract: Abnormalities in lipoprotein lipase (LPL) function contribute to the development of hypertriglyceridemia, one of the characteristic disorders observed in the metabolic syndrome. In addition to the hydrolyzing activity of triglycerides, LPL modulates various cellular functions via its binding ability to the cell surface. Here we show the effects of catalytically inactive LPL overexpression on high-fat diet (HFD)-induced decreased systemic insulin sensitivity in mice. The binding capacity of catalytically inactive G188E-LPL to C2C12 skeletal muscle cells was not significantly different from that of wild type LPL. Insulin-stimulated IRS-1 phosphorylation and glucose uptake were increased by addition of wild type or mutant LPL in C2C12 cells. After 10 weeks' of HFD feeding, mice had significantly higher blood glucose levels than chow-fed mice in insulin tolerance tests. The blood glucose levels after insulin injection was significantly decreased in mutated LPL-overexpressing mice (G188E mice), as well as in wild type LPL-overexpressing mice (WT mice). Overexpression of catalytically inactive LPL, as well as wild type LPL, improved impaired insulin sensitivity in mice. These results show that decreased expression of LPL possibly causes the insulin resistance, in addition to hypertriglyceridemia, in metabolic syndrome.
authors.affiliation: Department of Clinical Cell Biology (F5), Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shibasaki
authors.forename: H
authors.initials: H
authors.lastname: Bujo
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Murakami
authors.forename: H
authors.initials: H
authors.lastname: Unoki
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D016466:CHO Cells; D002478:Cells, Cultured; D006224:Cricetinae; D004041:Dietary Fats; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D055504:Insulin Receptor Substrate Proteins; D007333:Insulin Resistance / Q000502:physiology*; D008071:Lipoprotein Lipase / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008813:Mice, Inbred ICR; D008819:Mice, Nude; D018482:Muscle, Skeletal / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D014280:Triglycerides / Q000097:blood; D014443:Tyrosine / Q000378:metabolism
chemical_list: D004041:Dietary Fats; C526292:IRS1 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; C526295:Irs1 protein, mouse; D010750:Phosphoproteins; D014280:Triglycerides; D014443:Tyrosine; D008071:Lipoprotein Lipase; D005947:Glucose